L.P. Kotrekhova

L.P. Kotrekhova

Auto-generated profile, based on publicly available information

L.P. Kotrekhova

North-Western State Medical University Named After I.I. Mechnikov

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2023 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
MHM. A. S. Henning
M. A. S. Henning
RHR. Hay
R. Hay
Carmen Rodriguez-CerdeiraCarmen Rodriguez-Cerdeira
Carmen Rodriguez-Cerdeira
JSJ. C. Szepietowski
J. C. Szepietowski
Bianca Maria PiracciniBianca Maria Piraccini
Bianca Maria Piraccini
DSDitte Marie Lindhardt Saunte
Ditte Marie Lindhardt Saunte


20 May 2024 in Vestnik dermatologii i venerologii
Verified
Journal Article
Open access
PDF file
OOOlga Y. Olisova
Olga Y. Olisova
ESEvgeny V. Sokolovskiy
Evgeny V. Sokolovskiy
VKVladislav R. Khairutdinov
Vladislav R. Khairutdinov
MKMuza M. Kokhan
Muza M. Kokhan
MRMargarita R. Rakhmatulina
Margarita R. Rakhmatulina
СВСамцов Алексей Викторович
Самцов Алексей Викторович
Hidradenitis suppurativa (HS) is a chronic recurrent skin disease characterized by development of autoimmune inflammation in the infundibulum of the hair follicle and apocrine sweat glands located in the axillary, inguinal, anogenital regions, submammary folds, near the areola of mammary glands and the umbilical region. HS is difficult to treat and has an extremely negative impact on the quality of life. HS is separated into a distinct clinical entity fundamentally different in etiopathogenesis from acute bacterial hidradenitis. The exact prevalence of HS is unknown, it varies greatly in different studies ranging from 0.03 to 4% in general population. The detection of IL-1β, IL-23, and IL-17 in the lesions indicates the key role of autoimmune inflammation involving Th17-lymphocytes in the pathogenesis of HS. Risk factors include smoking, obesity, mechanical friction, genetic predisposition. The diagnosis of HS relies on three obligatory criteria: characteristic distribution, typical morphology of the lesions and relapsing, chronic disease course. There is no “gold standard” in assessing the severity of the disease, since all available scoring systems have many limitations, therefore many questions regarding this disease remain unsolved at present — from terminology and clear and most objective assessment criteria for the severity of the process to the development of native clinical guidelines.

7 February 2025 in Vestnik dermatologii i venerologii
Verified
Journal Article
Open access
PDF file
ASAlexey V. Samtsov
Alexey V. Samtsov
EAElena A. Araviyskaya
Elena A. Araviyskaya
LKLubov Pavlovna Kotrechova
Lubov Pavlovna Kotrechova
СВСамцов Алексей Викторович
Самцов Алексей Викторович
Background. Tinea pedis is a common superficial fungal skin infection. Amorolfine is one of the topical agents that have demonstrated efficacy in the treatment of mycoses. Aims. To assess and compare the efficacy of a new agent amorolfine 0.25% cream (Glenmark Pharmaceuticals Ltd., India), versus amorolfine 0.25% cream (Galderma Laboratory, France), registered in the European Union, in the treatment of tinea pedis. Methods. This open-label, randomized, multicenter, phase III study was conducted with adult patients with tinea pedis. Patients had once-daily amorolfine 0.25% cream (Glenmark Pharmaceuticals Ltd., India) or amorolfine 0.25% cream (Galderma Laboratory, France) applications to the affected skin areas for 28 days. The primary efficacy analysis was performed on the 42nd (± 4) day from the start of therapy, evaluating mycological (based on the results of a potassium hydroxide examination of skin scraping) and clinical (based on the results of symptoms and signs severity assessment) recovery. Results. In this clinical study,101 patients were randomized to the group 1 — amorolfine 0.25% cream (Glenmark Pharmaceuticals Ltd., India) and 99 patients to the group 2 — amorolfine 0.25% cream (Galderma Laboratory, France). The therapeutic equivalence of the study drugs was confirmed by the percentage of participants recovering as a result of therapy (mycological and clinical) by day 42, amounted to 95.0% in the group 1 and 97.0% in the group 2. The intergroup difference was –1.97% (90% confidence interval: –6.54; 2.60). The upper and lower limits of 90% confidence interval were within the established equivalence margin of 0.2 (р 0,0001). Among all registered adverse events, there were only 3 treatment-related associated: reaction at the site of application, erythema, and itching in group 2. There were no statistically significant differences between the groups in the incidence of adverse events. Conclusions. This study demonstrated the therapeutic equivalence of amorolfine 0.25% cream (Glenmark Pharmaceuticals Ltd., India) and amorolfine 0.25% cream (Galderma Laboratory, France). The safety profiles of the study drugs were acceptable and comparable.

1 January 2019 in Russian Journal of Clinical Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
LKL. P. Kotrekhova
L. P. Kotrekhova
GCG. A. Chilina
G. A. Chilina
IPI. M. Pchelin
I. M. Pchelin
ETE. N. Tsurupa
E. N. Tsurupa
KRK. I. Raznatovskiy
K. I. Raznatovskiy
NVN. V. Vasilyeva
N. V. Vasilyeva
Medical article медицинская статья

22 April 2024 in Russian Journal of Clinical Dermatology and Venereology
Verified
Journal Article
Closed access
LKL.P. Kotrekhova
L.P. Kotrekhova
Andrei AlekseevAndrei Alekseev
Andrei Alekseev
ETE.N. Tsurupa
E.N. Tsurupa
TBT.V. Bogdanova
T.V. Bogdanova
GCG.A. Chilina
G.A. Chilina
AVA.A. Vashkevich
A.A. Vashkevich
Superficial skin mycoses are the most common human’s fungal diseases. Their therapy by systemic and local antifungal drugs is effective in most cases. In recent times, the number of cases of ineffective application of antifungal drugs in regimen recommended by clinical guidelines and medicines’ instructions increased. Prescription of therapy schemes involving simultaneous use of several antifungal drugs allows overcoming low effectiveness of antifungal monotherapy. The number of clinical cases of superficial skin mycoses equal 2 was described: malassezia folliculitis (causative agent — Malassezia sympodialis) and disseminated microsporidiosis (causative agent — Microsporum canis), that at first were poorly responded to antifungal therapy, but eventually were completely cured. Malassezia folliculitis in 18-years-old patient, who took 60 mg/day prednisolone calculated as 1 mg/kg/day and 100 mg/day azathioprine due to pyoderma gangrenosum, was cured by combination of solution with 2% sertaconazole and shampoo with 2% ketoconazole and 1% zinc pyrithione. Moreover, after recovery, further use of shampoo with 2% ketoconazole and 1% zinc pyrithione in a preventive treatment regimen, namely 1—2 times per week, while remaining immunosuppressive state associated with the treatment of pyoderma gangrenosum allowed to predict Malassezia folliculitis recurrence. The combination of griseofulvin application, ingested at a dose of 750 mg/day calculated as 22 mg/kg/day, and local therapy by solution with sertaconazole and shampoo with ketoconazole and zinc pyrithione, was effective in disseminated microsporidiosis of smooth skin with damage of lanugo. Combined therapy with the use of medical antifungal two-component shampoo allowed to increase the treatment effectiveness, accelerate patients’ recovery, prevent the distribution of mycotic infection during washing, and the use of antifungal shampoo in a preventive regimen, namely 1—2 times per week, when long-term immunosuppression — to prevent the recurrence of malassezia-folliculitis.